Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial

被引：24

作者：

Groothius, JR ^{[1
]}

机构：

[1] Abbott Int, No Hemisphere Expanded Access Study Grp, Abbott Pk, IL USA

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2001年 / 20卷 / 06期

关键词：

respiratory syncytial virus; premature infants; monoclonal antibodies; bronchopulmonary dysplasia; chronic lung disease; respiratory disease; infectious disease;

D O I：

10.1097/00006454-200106000-00018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

An Expanded Access Study was conducted to collect additional safety data on palivizumab. Pre-term infants with or without bronchopulmonary dysplasia received palivizumab every 30 days during the respiratory syncytial virus season. Adverse events were low (6.9%) in the 565 subjects. Serious adverse events included hospitalization and 1 case of respiratory syncytial virus bronchiolitis not requiring hospitalization. This study reaffirms the safety and tolerability of palivizumab.

引用

页码：628 / 630

页数：3

共 7 条

[1] Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid
Boyce, TG
Mellen, BG
Mitchel, EF
Wright, PF
Griffin, MR
[J]. JOURNAL OF PEDIATRICS, 2000, 137 (06) : 865 - 870
[2] Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation:: a prospective study
Carbonell-Estrany, X
Quero, J
Bustos, G
Cotero, A
Doménech, E
Figueras-Aloy, J
Fraga, JM
García, LG
García-Alix, A
Del Río, MG
Krauel, X
Sastre, JBL
Narbona, E
Roqués, V
Hernández, SS
Zapatero, M
[J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (07) : 592 - 597
[3] CUNNINGHAM CK, 1991, PEDIATRICS, V88, P527
[4] Hall C.B., 1992, TXB PEDIAT INFECT DI, P1633
[5] Halsey NA, 1998, PEDIATRICS, V102, P1211, DOI 10.1542/peds.102.5.1211
[6] *ICH HARM TRIP GUI, 1998, INT C HARM WEBS
[7] Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531

← 1 →